Arterial Embolus And Thrombosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for arterial embolus and thrombosis. 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
16
Active US patents
72/100
Avg vulnerability
$14.4B
Annual revenue covered

Originators in Arterial Embolus And Thrombosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 16 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating arterial embolus and thrombosis. Each bar = one year. Y-axis scaled to peak year (6 patents).

4
26
4
27
6
31
1
40
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Eliquis
apixaban
 Bristol-Myers Squibb 16 72 $14.4B 2026-11-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
6967208 Eliquis method of use 93 2026-11-21
6967208 Eliquis method of use 93 2026-11-21
6967208 Eliquis method of use 85 2026-11-21
6967208 Eliquis method of use 85 2026-11-21
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21
11896586 Eliquis method of use 75 2040-11-22
9326945 Eliquis other 68 2031-08-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9326945 Eliquis formulation 48 2031-02-24
9326945 Eliquis formulation 48 2031-02-24
9326945 Eliquis formulation 61 2031-02-24
11896586 Eliquis other 62 2041-05-22
9326945 Eliquis other 68 2031-08-24
9326945 Eliquis other 68 2031-08-24
9326945 Eliquis other 68 2031-08-24
11896586 Eliquis method of use 75 2040-11-22
6967208 Eliquis other 75 2027-05-21
6967208 Eliquis other 75 2027-05-21

Related